The DOI matches its OpenAlex record; 3 of the 3 references it cites were found in a registry or an index.
Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c
Open accessAbstract
We explored the effects of bile acids on triglyceride (TG) homeostasis using a combination of molecular, cellular, and animal models. Cholic acid (CA) prevents hepatic TG accumulation, VLDL secretion, and elevated serum TG in mouse models of hypertriglyceridemia. At the molecular level, CA decreases hepatic expression of SREBP-1c and its lipogenic target genes. Through the use of mouse mutants for the short heterodimer partner (SHP) and liver X receptor (LXR) alpha and beta, we demonstrate the critical dependence of the reduction of SREBP-1c expression by either natural or synthetic farnesoid X receptor (FXR) agonists on both SHP and LXR alpha and LXR beta. These results suggest that strategies aimed at increasing FXR activity and the repressive effects of SHP should be explored to correct hypertriglyceridemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Liang, G., Yang, J., Horton, J. D., Hammer, R. E., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111421200 · Cited by 669
Hypertriglyceridemia: a contraindication to the use of bile acid binding resins.
Crouse, J. R. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90692-9 · Cited by 130
Cited by
Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., et al. (2006) · Cell · doi:10.1016/j.cell.2006.11.013 · Cited by 4,057
Self-citationGut microbiota functions: metabolism of nutrients and other food components
Rowland, I., Gibson, G., Heinken, A., Scott, K., Swann, J., Thiele, I., & Tuohy, K. (2018) · European Journal of Nutrition · doi:10.1007/s00394-017-1445-8 · Cited by 2,878
“Through binding to these receptors, bile acids can regulate genes critical to their synthesis, conjugation, transport, and detoxification [75–77] as well as lipid [78, 79] and glucose metabolism [80, 81] and energy homeostasis [82].”
BackgroundBile acids induce energy expenditure by promoting intracellular thyroid hormone activation
Watanabe, M., Houten, S. M., Mataki, C., Christoffolete, M. A., Kim, B. W., Sato, H., Messaddeq, N., Harney, J. W., Ezaki, O., Kodama, T., et al. (2006) · Nature · doi:10.1038/nature04330 · Cited by 2,220
Self-citationTGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis
Thomas, C., Gioiello, A., Noriega, L., Strehle, A., Oury, J., Rizzo, G., Macchiarulo, A., Yamamoto, H., Mataki, C., Pruzanski, M., et al. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.08.001 · Cited by 1,885
Self-citationRole of Bile Acids and Bile Acid Receptors in Metabolic Regulation
Lefebvre, P., Cariou, B., Lien, F., Kuipers, F., & Staels, B. (2009) · Physiological Reviews · doi:10.1152/physrev.00010.2008 · Cited by 1,678
Targeting bile‐acid signalling for metabolic diseases
Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx, J., & Schoonjans, K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2619 · Cited by 1,422
Self-citationGodoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
The Opposing Effects of N-3 and n-6 Fatty Acids
Schmitz, G., & Ecker, J. (2008) · Progress in Lipid Research · doi:10.1016/j.plipres.2007.12.004 · Cited by 1,245
Pleiotropic Roles of Bile Acids in Metabolism
de Aguiar Vallim, T. Q., Tarling, E. J., & Edwards, P. A. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.03.013 · Cited by 1,209
Bile acids and the gut microbiota: metabolic interactions and impacts on disease
Collins, S. L., Stine, J. G., Bisanz, J. E., Okafor, C. D., & Patterson, A. D. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00805-x · Cited by 1,214
Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network
Bookout, A. L., Jeong, Y., Downes, M., Yu, R. T., Evans, R. M., & Mangelsdorf, D. J. (2006) · Cell · doi:10.1016/j.cell.2006.06.049 · Cited by 1,015
Self-citationChávez-Talavera, O., Tailleux, A., Lefebvre, P., & Staels, B. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.055 · Cited by 970
Bile acid signaling in metabolic disease and drug therapy
Li, T., & Chiang, J. Y. L. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.008201 · Cited by 935
Lipotoxicity and the gut-liver axis in NASH pathogenesis
Marra, F., & Svegliati-Baroni, G. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.014 · Cited by 847
Bile Acids Control Inflammation and Metabolic Disorder through Inhibition of NLRP3 Inflammasome
Guo, C., Xie, S., Chi, Z., Zhang, J., Liu, Y., Zhang, L., Zheng, M., Zhang, X., Xia, D., Ke, Y., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.09.008 · Cited by 838
Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR
Calkin, A. C., & Tontonoz, P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3312 · Cited by 779
Jiao, N., Baker, S. S., Chapa-Rodriguez, A., Liu, W., Nugent, C. A., Tsompana, M., Mastrandrea, L., Buck, M. J., Baker, R. D., Genco, R. J., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-314307 · Cited by 737
Systemic gut microbial modulation of bile acid metabolism in host tissue compartments
Swann, J. R., Want, E. J., Geier, F. M., Spagou, K., Wilson, I. D., Sidaway, J. E., Nicholson, J. K., & Holmes, E. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006734107 · Cited by 726
Bile acids as regulatory molecules
Hylemon, P. B., Zhou, H., Pandak, W. M., Ren, S., Gil, G., & Dent, P. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r900007-jlr200 · Cited by 694
Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease
Jiang, C., Xie, C., Li, F., Zhang, L., Nichols, R. G., Krausz, K. W., Cai, J., Qi, Y., Fang, Z.-Z., Takahashi, S., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci76738 · Cited by 693
Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives
Arab, J. P., Karpen, S. J., Dawson, P. A., Arrese, M., & Trauner, M. (2017) · Hepatology · doi:10.1002/hep.28709 · Cited by 634
Patti, M., Houten, S. M., Bianco, A. C., Bernier, R., Larsen, P. R., Holst, J. J., Badman, M. K., Maratos‐Flier, E., Mun, E. C., Pihlajamaki, J., et al. (2009) · Obesity · doi:10.1038/oby.2009.102 · Cited by 591
Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy
Chiang, J. Y. L., & Ferrell, J. M. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00223.2019 · Cited by 580
Recent insights into the pathogenesis of nonalcoholic fatty liver disease
Arab, J. P., Arrese, M., & Trauner, M. (2018) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-043617 · Cited by 573
New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond
Beuers, U., Trauner, M., Jansen, P., & Poupon, R. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.023 · Cited by 537
Circadian Homeostasis of Liver Metabolism Suppresses Hepatocarcinogenesis
Kettner, N. M., Voicu, H., Finegold, M. J., Coarfa, C., Sreekumar, A., Putluri, N., Katchy, C. A., Lee, C., Moore, D. D., & Fu, L. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.10.007 · Cited by 508
“Ablation of Nr1h4 (hereafter referred to as Fxr) not only promotes cholestasis but also NAFLD, NASH and HCC in mice (Kim et al., 2007; Lu et al., 2000; Wang et al., 2008; Watanabe et al., 2004; Yang et al., 2007).”
BackgroundSelf-citationBile acid nuclear receptor FXR and digestive system diseases
Ding, L., Yang, L., Wang, Z., & Huang, W. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.01.004 · Cited by 477
Molecular physiology of bile acid signaling in health, disease, and aging
Perino, A., Demagny, H., Velazquez-Villegas, L., & Schoonjans, K. (2021) · Physiological Reviews · doi:10.1152/physrev.00049.2019 · Cited by 481
Bile Acids as Hormones: The FXR-FGF15/19 Pathway
Kliewer, S. A., & Mangelsdorf, D. J. (2015) · Digestive Diseases · doi:10.1159/000371670 · Cited by 424
Self-citationKim, Y. D., Park, K.-G., Lee, Y.-S., Park, Y.-Y., Kim, D.-K., Nedumaran, B., Jang, W. G., Cho, W.-J., Ha, J., Lee, I.-K., et al. (2008) · Diabetes · doi:10.2337/db07-0381 · Cited by 422
Martin, F. J., Wang, Y., Sprenger, N., Yap, I. K. S., Lundstedt, T., Lek, P., Rezzi, S., Ramadan, Z., van Bladeren, P., Fay, L. B., et al. (2008) · Molecular Systems Biology · doi:10.1038/msb4100190 · Cited by 421
FXR: a metabolic regulator and cell protector
Wang, Y.-D., Chen, W.-D., Moore, D. D., & Huang, W. (2008) · Cell Research · doi:10.1038/cr.2008.289 · Cited by 389
Self-citationChu, H., Duan, Y., Yang, L., & Schnabl, B. (2019) · Gut · doi:10.1136/gutjnl-2018-316307 · Cited by 354
FXR, a multipurpose nuclear receptor
Lee, F. Y., Lee, H., Hubbert, M. L., Edwards, P. A., & Zhang, Y. (2006) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2006.08.002 · Cited by 344
A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis
Ratziu, V., de Ledinghen, V., Oberti, F., Mathurin, P., Wartelle-Bladou, C., Renou, C., Sogni, P., Maynard, M., Larrey, D., Serfaty, L., et al. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.08.030 · Cited by 338
Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis
Gomez-Ospina, N., Potter, C. J., Xiao, R., Manickam, K., Kim, M.-S., Kim, K. H., Shneider, B. L., Picarsic, J. L., Jacobson, T. A., Zhang, J., et al. (2016) · Nature Communications · doi:10.1038/ncomms10713 · Cited by 300
Self-citationMature-onset obesity and insulin resistance in mice deficient in the signaling adapter p62
Rodriguez, A., Durán, A., Selloum, M., Champy, M.-F., Diez-Guerra, F. J., Flores, J. M., Serrano, M., Auwerx, J., Diaz-Meco, M. T., & Moscat, J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.011 · Cited by 290
Self-citationZhang, S., Wang, J., Liu, Q., & Harnish, D. C. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.03.025 · Cited by 290
Inter-organ cross-talk in metabolic syndrome
Priest, C., & Tontonoz, P. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0145-5 · Cited by 279
Jones, M. L., Martoni, C. J., & Prakash, S. (2012) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2012.126 · Cited by 277
The gut microbiota drives the impact of bile acids and fat source in diet on mouse metabolism
Just, S., Mondot, S., Ecker, J., Wegner, K., Rath, E., Gau, L., Streidl, T., Hery-Arnaud, G., Schmidt, S., Lesker, T. R., et al. (2018) · Microbiome · doi:10.1186/s40168-018-0510-8 · Cited by 269
Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis
Adorini, L., Pruzanski, M., & Shapiro, D. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.05.012 · Cited by 259
A dysregulated bile acid-gut microbiota axis contributes to obesity susceptibility
Wei, M., Huang, F., Zhao, L., Zhang, Y., Yang, W., Wang, S., Li, M., Han, X., Ge, K., Qu, C., et al. (2020) · eBioMedicine · doi:10.1016/j.ebiom.2020.102766 · Cited by 253
Intestinal absorption of bile acids in health and disease
Ticho, A. L., Malhotra, P., Dudeja, P. K., Gill, R. K., & Alrefai, W. A. (2019) · Comprehensive physiology · doi:10.1002/cphy.c190007 · Cited by 215
Sun, R., Yang, N., Kong, B., Cao, B., Feng, D., Yu, X., Ge, C., Huang, J., Shen, J., Wang, P., et al. (2017) · Molecular Pharmacology · doi:10.1124/mol.116.106617 · Cited by 199
Nakatani, H., Kasama, K., Oshiro, T., Watanabe, M., Hirose, H., & Itoh, H. (2009) · Metabolism · doi:10.1016/j.metabol.2009.05.006 · Cited by 192
Mencarelli, A., Renga, B., Migliorati, M., Cipriani, S., Distrutti, E., Santucci, L., & Fiorucci, S. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901347 · Cited by 177
Bile Acids, Obesity, and the Metabolic Syndrome
Ma, H., & Patti, M. E. (2014) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2014.07.004 · Cited by 176
Bile acids and their receptors
Martinot, E., Sèdes, L., Baptissart, M., Lobaccaro, J.-M., Caira, F., Beaudoin, C., & Volle, D. H. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.01.006 · Cited by 162
Dietary Protein and Energy Balance in Relation to Obesity and Co-morbidities
Drummen, M., Tischmann, L., Gatta-Cherifi, B., Adam, T., & Westerterp-Plantenga, M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00443 · Cited by 156
High protein intake reduces intrahepatocellular lipid deposition in humans
Bortolotti, M., Kreis, R., Debard, C., Cariou, B., Faeh, D., Chetiveaux, M., Ith, M., Vermathen, P., Stefanoni, N., Lê, K.-A., et al. (2009) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.27296 · Cited by 146
Simonen, M., Dali-Youcef, N., Kaminska, D., Venesmaa, S., Käkelä, P., Pääkkönen, M., Hallikainen, M., Kolehmainen, M., Uusitupa, M., Moilanen, L., et al. (2012) · Obesity Surgery · doi:10.1007/s11695-012-0673-5 · Cited by 145
Self-citationHepatic transcriptional responses to fasting and feeding
Bideyan, L., Nagari, R., & Tontonoz, P. (2021) · Genes & Development · doi:10.1101/gad.348340.121 · Cited by 126
Tiwari, A., & Maiti, P. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.02.005 · Cited by 122
Bile acids: From digestion to cancers
Baptissart, M., Vega, A., Maqdasy, S., Caira, F., Baron, S., Lobaccaro, J.-M. A., & Volle, D. H. (2013) · Biochimie · doi:10.1016/j.biochi.2012.06.022 · Cited by 97
Diet-induced gut dysbiosis and inflammation: Key drivers of obesity-driven NASH
Kang, G. G., Trevaskis, N. L., Murphy, A. J., & Febbraio, M. A. (2023) · iScience · doi:10.1016/j.isci.2022.105905 · Cited by 94
Gut adaptation after metabolic surgery and its influences on the brain, liver and cancer
Sinclair, P., Brennan, D. J., & le Roux, C. W. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0057-y · Cited by 91
Bouitbir, J., Charles, A.-L., Rasseneur, L., Dufour, S., Piquard, F., Geny, B., & Zoll, J. (2011) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00107.2011 · Cited by 86
Martoni, C. J., Labbé, A., Ganopolsky, J. G., Prakash, S., & Jones, M. L. (2015) · Gut Microbes · doi:10.1080/19490976.2015.1005474 · Cited by 87
Nonsteroidal FXR Ligands: Current Status and Clinical Applications
Gege, C., Hambruch, E., Hambruch, N., Kinzel, O., & Kremoser, C. (2019) · Handbook of Experimental Pharmacology · doi:10.1007/164_2019_232 · Cited by 83
Role of bile acids in the regulation of the metabolic pathways
Taoka, H., Yokoyama, Y., Morimoto, K., Kitamura, N., Tanigaki, T., Takashina, Y., Tsubota, K., & Watanabe, M. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i13.260 · Cited by 80
Miyata, M., Sakaida, Y., Matsuzawa, H., Yoshinari, K., & Yamazoe, Y. (2011) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.34.1885 · Cited by 77
Miyata, M., Takamatsu, Y., Kuribayashi, H., & Yamazoe, Y. (2009) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.160093 · Cited by 72
Park, Y. J., Qatanani, M., Chua, S. S., LaRey, J. L., Johnson, S. A., Watanabe, M., Moore, D. D., & Lee, Y. K. (2008) · Hepatology · doi:10.1002/hep.22196 · Cited by 68
Self-citationFerrell, J. M., Pathak, P., Boehme, S., Gilliland, T., & Chiang, J. Y. L. (2019) · Hepatology · doi:10.1002/hep.30513 · Cited by 65
Han, C. Y., Ki, S. H., Kim, Y. W., Noh, K., Lee, D. Y., Kang, B., Ryu, J.-H., Jeon, R., Kim, E. H., Hwang, S. J., et al. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3190 · Cited by 63
5β-Reduced steroids and human Δ4-3-ketosteroid 5β-reductase (AKR1D1)
Chen, M., & Penning, T. M. (2014) · Steroids · doi:10.1016/j.steroids.2014.01.013 · Cited by 55
Mouse phenogenomics: the fast track to “systems metabolism
Argmann, C. A., Chambon, P., & Auwerx, J. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.11.002 · Cited by 51
Self-citationThe interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease
Finney, A. C., Das, S., Kumar, D., McKinney, M. P., Cai, B., Yurdagul, A., & Rom, O. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1116861 · Cited by 40
Bacterial metabolites directly modulate farnesoid X receptor activity
Zhang, X., Osaka, T., & Tsuneda, S. (2015) · Nutrition & Metabolism · doi:10.1186/s12986-015-0045-y · Cited by 34
Farnesoid X receptor alpha: a molecular link between bile acids and steroid signaling
Baptissart, M., Vega, A., Martinot, E., Baron, S., Lobaccaro, J.-M. A., & Volle, D. H. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1387-0 · Cited by 32
[Retracted] A Review of Bile Acid Metabolism and Signaling in Cognitive Dysfunction‐Related Diseases
Weng, Z.-B., Chen, Y.-R., Lv, J.-T., Wang, M.-X., Chen, Z.-Y., Zhou, W., Shen, X.-C., Zhan, L.-B., & Wang, F. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/4289383 · Cited by 32
“There are two known pathways: the intestinal FXR/FGF19/ FGFR4 pathway [14] and the hepatic FXR/SHP pathway [45, 46].”
RetractedVascular targets for the treatment of portal hypertension
Brusilovskaya, K., Königshofer, P., Schwabl, P., & Reiberger, T. (2019) · Seminars in Liver Disease · doi:10.1055/s-0039-1693115 · Cited by 28
Martens, E. A., Gatta-Cherifi, B., Gonnissen, H. K., & Westerterp-Plantenga, M. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109617 · Cited by 21
Nuclear receptors and liver disease: summary of the 2017 basic research symposium
Tran, M., Liu, Y., Huang, W., & Wang, L. (2018) · Hepatology Communications · doi:10.1002/hep4.1203 · Cited by 20
Self-citationThe Administration of Probiotics against Hypercholesterolemia: A Systematic Review
Sivamaruthi, B. S., Bharathi, M., Kesika, P., Suganthy, N., & Chaiyasut, C. (2021) · Applied Sciences · doi:10.3390/app11156913 · Cited by 20
Chen, H., Cao, T., Zhang, B., & Cai, H. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1097284 · Cited by 18
Metadata
- Authors
- 渡辺, 光., Houten, S. M., Wang, L., Moschetta, A., Mangelsdorf, D. J., Heyman, R. A., Moore, D. D., & Auwerx, J. H.
- Venue
- Journal of Clinical Investigation
- Publisher
- American Society for Clinical Investigation
- Published
- 2004-05-15
- Volume
- 113
- Issue
- 10
- Pages
- 1408-1418
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1966922165
- Cited by
- 1,397
- References
- 3
- FWCI
- 21.89
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
